For Healthcare Professionals Outside the US

For patients with BRAF V600 mutation–positive unresectable or metastatic melanoma

High Rates of Durable Responses4,5

  • Up to 69% of patients responded to therapy4
  • Median duration of response up to 13.8 months5

Find out more

Well-Characterized and Consistent Safety Profile4-6

Across 2 phase 3 studies, Tafinlar + Mekinist demonstrated similar incidences of AEs and discontinuation rates compared with BRAF inhibitor monotherapy4,6

Find out more

Initiate First-Line Treatment With Tafinlar® + Mekinist®

For patients with BRAF V600 mutation–positive unresectable or metastatic melanoma7

Find out more

References:  1. Long GV, Weber JS, Infante JR, et al. Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. J Clin Oncol. 2016;34(8):871-878. 2. Schadendorf D, Amonkar MM, Stroyakovskiy D, et al. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. Eur J Cancer. 2015;51(7):833-840. 3. Grob J-J, Amonkar MM, Karaszewska B, et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol. 2015;16(13):1389-1398. 4. Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444-451. 5. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30-39. 6. Tafinlar (dabrafenib) [summary of product characteristics]. West Sussex, UK: Novartis Europharm Limited; 2015.